4D Pharma to Host Virtual KOL Event on Asthma Treatment Landscape and Review of Positive Topline Results from Part A Phase I/II Trial of MRx-4DP0004 | News

LEEDS, England–(BUSINESS WIRE)–January 20, 2022–

4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of living biotherapeutics (LBPs), a new class of drugs derived from the microbiome, today announced that it will host a virtual Key Opinion Leader (KOL) event to review key positive findings previously disclosed Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of asthma and to discuss the asthma treatment landscape. The event will take place on Thursday, January 27, 2022 starting at 8:00 a.m. ET (1:00 p.m. GMT).

The event will include presentations from 4D pharma management and KOL, Professor Chris Brightling, Senior Researcher and Clinical Professor of Respiratory Medicine at the National Institute for Health Research (NIHR), Department of Respiratory Sciences, University of Leicester, UK, and principal investigator of the MRx -4DP0004 Phase I/II trial.

A live webcast of the event will be available in the Reports and Presentations section of the 4D Pharma website at www.4dpharmaplc.com. A replay of the webcast and accompanying slides will be available on the 4D pharma website after the event.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a new emerging class of drugs, defined by the FDA as biological products containing a living organism, such as a bacterium, applicable to the prevention, treatment or cure of A disease. 4D has developed a proprietary platform, MicroRx®, which rationally identifies living biotherapies based on an in-depth understanding of function and mechanism. 4D pharma’s Live Biotherapeutic Products (LBPs) are unique strains of bacteria found naturally in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma and Blautix® in irritable bowel syndrome (IBS) which successfully completed a phase II trial. Preclinical-stage programs include candidates for CNS diseases such as Parkinson’s disease and other neurodegenerative conditions. The company has a research collaboration with MSD, a trade name of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop live biotherapeutics for vaccines.

For more information, see https://www.4dpharmaplc.com

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220120005125/en/

CONTACT: 4D

Duncan Peyton, Managing Director +44 (0)113 895 0130

Investor Relationsir@4dpharmaplc.comSinger Capital Markets – Appointed Advisor and Associate Broker+44 (0)20 7496 3000

Philip Davies / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)Bryan Garnier & Co. Limited – Co-broker +44 (0)20 7332 2500

Dominic WilsonStern Investor Relations

Julie Seidel+1-212-362-1200

Julie.seidel@sternir.comImage Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 46856 Degrees

Lynne Dardanell +1-336-202-9689

ldardanell@6degreespr.com

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: HEALTHCARE OTHER SCIENCE CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: 4D pharma plc

Copyright BusinessWire 2022.

PUBLISHED: 01/20/2022 07:00/DISC: 01/20/2022 07:02

http://www.businesswire.com/news/home/20220120005125/en

Copyright BusinessWire 2022.

Comments are closed.